JPWO2006118212A1 - 膵炎の予防および治療剤 - Google Patents
膵炎の予防および治療剤 Download PDFInfo
- Publication number
- JPWO2006118212A1 JPWO2006118212A1 JP2007514816A JP2007514816A JPWO2006118212A1 JP WO2006118212 A1 JPWO2006118212 A1 JP WO2006118212A1 JP 2007514816 A JP2007514816 A JP 2007514816A JP 2007514816 A JP2007514816 A JP 2007514816A JP WO2006118212 A1 JPWO2006118212 A1 JP WO2006118212A1
- Authority
- JP
- Japan
- Prior art keywords
- ht2a receptor
- binding activity
- pancreatitis
- ht2a
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 **Oc1c(CCc2ccccc2)cccc1 Chemical compound **Oc1c(CCc2ccccc2)cccc1 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9406—Neurotransmitters
- G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/067—Pancreatitis or colitis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
5−HT1A、5−HT1B、5−HT1D、5−HT1E、5−HT1F
5−HT2A、5−HT2B、5−HT2C
5−HT3、5−HT4、5−HT5A、5−HT5B、5−HT6、5−HT7
5−HT2A : 血管平滑筋、血小板、肺、中枢神経、消化管に存在する。血管収縮と血小板凝固、血小板からのセロトニン遊離に関連する。
5−HT2B : 主に末梢に存在し、脳にも存在する。ラットの胃底部筋収縮に関連する。血管の弛緩に関連する。
5−HT2C : 中枢神経に存在し、末梢にも存在する。摂食機能、自動運動に関連する。血管の弛緩に関連する。
Ki = IC50/(1+L/ Kd)
結合活性(pKi)は、pKi=-logKiである。
を有する化合物ではない。
5週齢のマウスにセルレイン水溶液(0.05mg/Kg)を1時間おきに5回皮下注射により投与した。5−HT2拮抗剤は、溶媒(生理食塩水中0.5%メチルセルロース)に懸濁して、最初にセルレインを投与する15分前に背部皮下に投与した。5−HT2拮抗剤としては、ケタンセリン(Katanserin)(5−HT2A/C拮抗剤)、SB204741(5−HT2B拮抗剤)、SB242084(5−HT2C拮抗剤)を、それぞれ図に示される用量で用いた。また、対照群(セルレイン単独投与群)には、溶媒のみを背部皮下に投与した。最終投与の1時間後に血液を採取して、血漿中のアミラーゼ、リパーゼ活性を測定した。
Claims (8)
- 膵炎の予防剤および治療剤の候補物質の同定方法であって、試験物質の5−HT2A受容体および5−HT2Bに対する結合活性(pKi)を測定し、5−HT2A受容体に対する結合活性が5−HT2B受容体に対する結合活性より1.0以上高い場合に、その試験物質を膵炎の予防剤および治療剤の候補物質として同定することを含む方法。
- さらに、試験物質の5−HT2Cに対する結合活性を測定し、5−HT2A受容体に対する結合活性が5−HT2Bおよび5−HT2C受容体に対する結合活性より1.0以上高い場合に、その試験物質を膵炎の予防剤および治療剤の候補物質として同定することを含む、請求項1記載の方法。
- 5−HT2A受容体拮抗剤を有効成分とする膵炎を予防および治療するための医薬組成物であって、前記5−HT2A受容体拮抗剤は、5−HT2A受容体に対する結合活性(pKi)が5−HT2B受容体に対する結合活性より1.0以上高いことを特徴とし;
ただし、前記5−HT2A受容体拮抗剤は、ケタンセリン、塩酸サルポグレラート、または次式:
を有する化合物ではない、
ことを特徴とする医薬組成物。 - 前記5−HT2A受容体拮抗剤は、5−HT2A受容体に対する結合活性(pKi)が5−HT2C受容体に対する結合活性より1.0以上高いものである、請求項3記載の医薬組成物。
- 前記5−HT2A受容体拮抗剤の5−HT2A受容体に対する結合活性(pKi)が7.0以上である、請求項3記載の医薬組成物。
- 前記5−HT2A受容体拮抗剤の5−HT2A受容体に対する結合活性(pKi)が8.0以上である、請求項3記載の医薬組成物。
- 前記5−HT2A受容体拮抗剤の5−HT2A受容体に対する結合活性(pKi)が9.0以上である、請求項3記載の医薬組成物。
- 5−HT2A受容体拮抗剤が、リスペリドン、ジプラシドン、パリペリドン、イロペリドン、ケチアピン、ネファゾドン、ペロスピロン、アリピプラゾール、ゾテピン、ミルタザピン、セルチンドール、アセナピン、ブロナンセリン、スピペロン、クロザピン、アンペロジド、オランザピン、クロルプロマジン、ハロペリドールからなる群より選択される、請求項3記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005130408 | 2005-04-27 | ||
JP2005130408 | 2005-04-27 | ||
PCT/JP2006/308880 WO2006118212A1 (ja) | 2005-04-27 | 2006-04-27 | 膵炎の予防および治療剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPWO2006118212A1 true JPWO2006118212A1 (ja) | 2008-12-18 |
Family
ID=37308010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007514816A Pending JPWO2006118212A1 (ja) | 2005-04-27 | 2006-04-27 | 膵炎の予防および治療剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US20090075974A1 (ja) |
EP (1) | EP1879027B1 (ja) |
JP (1) | JPWO2006118212A1 (ja) |
KR (1) | KR20080012896A (ja) |
CN (1) | CN101198869A (ja) |
AU (1) | AU2006241806B2 (ja) |
BR (1) | BRPI0607669A2 (ja) |
CA (1) | CA2607524A1 (ja) |
RU (1) | RU2423692C2 (ja) |
WO (1) | WO2006118212A1 (ja) |
ZA (1) | ZA200709561B (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3261645T3 (da) | 2015-02-27 | 2021-06-07 | Dechra Ltd | Stimulering af appetit, håndtering af vægttab og behandling af anoreksi hos hunde og katte |
WO2017023047A1 (ko) * | 2015-08-03 | 2017-02-09 | 성균관대학교산학협력단 | 아리피프라졸을 유효성분으로 함유하는 염증성 질환 또는 암 예방 또는 치료용 조성물 |
EP3558276A1 (en) | 2016-12-20 | 2019-10-30 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
MX2019007391A (es) | 2016-12-20 | 2019-08-16 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico que contiene asenapina. |
WO2019002204A1 (en) | 2017-06-26 | 2019-01-03 | Lts Lohmann Therapie-Systeme Ag | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER |
WO2019243452A1 (en) | 2018-06-20 | 2019-12-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine |
WO2024006226A1 (en) * | 2022-06-26 | 2024-01-04 | Alexander Shulgin Research Institute, Inc. | N-substituted phenylalkylamines and their use as therapeutic agents |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3968388B2 (ja) | 1996-03-18 | 2007-08-29 | 第一三共株式会社 | 膵炎治療剤 |
JPH10212232A (ja) | 1996-11-28 | 1998-08-11 | Sankyo Co Ltd | ジアリールアルカン誘導体を有効成分とする膵炎治療剤又は予防剤 |
JP2000063270A (ja) | 1998-08-20 | 2000-02-29 | Mitsubishi Chemicals Corp | 膵炎の予防・治療剤 |
EP1982980A1 (en) * | 2000-08-14 | 2008-10-22 | Teva Pharmaceutical Industries Ltd. | Crystalline form of risperidone |
JP4240973B2 (ja) * | 2002-09-26 | 2009-03-18 | ソニー株式会社 | 画像処理システム、画像処理装置および方法、記録媒体、並びにプログラム |
JP2005130408A (ja) | 2003-10-27 | 2005-05-19 | Fujitsu Ltd | リンク集約方法およびリンク集約スイッチ |
-
2006
- 2006-04-27 KR KR1020077027446A patent/KR20080012896A/ko active IP Right Grant
- 2006-04-27 CA CA002607524A patent/CA2607524A1/en not_active Abandoned
- 2006-04-27 EP EP06732431.9A patent/EP1879027B1/en not_active Not-in-force
- 2006-04-27 BR BRPI0607669-6A patent/BRPI0607669A2/pt not_active IP Right Cessation
- 2006-04-27 US US11/912,737 patent/US20090075974A1/en not_active Abandoned
- 2006-04-27 JP JP2007514816A patent/JPWO2006118212A1/ja active Pending
- 2006-04-27 CN CNA2006800217638A patent/CN101198869A/zh active Pending
- 2006-04-27 AU AU2006241806A patent/AU2006241806B2/en not_active Ceased
- 2006-04-27 WO PCT/JP2006/308880 patent/WO2006118212A1/ja active Application Filing
- 2006-04-27 RU RU2007143980/15A patent/RU2423692C2/ru not_active IP Right Cessation
-
2007
- 2007-11-06 ZA ZA200709561A patent/ZA200709561B/xx unknown
Non-Patent Citations (5)
Also Published As
Publication number | Publication date |
---|---|
US20090075974A1 (en) | 2009-03-19 |
CA2607524A1 (en) | 2006-11-09 |
EP1879027A1 (en) | 2008-01-16 |
RU2007143980A (ru) | 2009-06-10 |
ZA200709561B (en) | 2009-08-26 |
BRPI0607669A2 (pt) | 2009-09-22 |
EP1879027A4 (en) | 2009-01-07 |
WO2006118212A1 (ja) | 2006-11-09 |
EP1879027B1 (en) | 2013-06-12 |
RU2423692C2 (ru) | 2011-07-10 |
CN101198869A (zh) | 2008-06-11 |
KR20080012896A (ko) | 2008-02-12 |
AU2006241806A1 (en) | 2006-11-09 |
AU2006241806B2 (en) | 2012-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2904447C (en) | Therapy for complications of diabetes | |
JP6337170B2 (ja) | ネコの全身性疾患の予防又は治療の為のアンジオテンシンii受容体アンタゴニスト | |
US20050014783A1 (en) | Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy | |
JPWO2006118212A1 (ja) | 膵炎の予防および治療剤 | |
EA020466B1 (ru) | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний | |
IL172693A (en) | Use of angiotensin II receptor antagonists, especially telemisartan to increase the sensitivity of insulin and its pharmacological preparations | |
CA3113376A1 (en) | Compositions for reducing serum uric acid | |
MX2011000511A (es) | Uso de derivados de pirimidil-amino-benzamida para el tratamiento de fibrosis. | |
KR20020010527A (ko) | 기능적 건강 상태를 향상시키기 위한 성장 호르몬분비촉진물질을 포함하는 약학 조성물 | |
US20150216794A1 (en) | Methods of treating pain associated with osteoarthritis of a joint with a topical formulation of a spiro-oxindole compound | |
JP6373275B2 (ja) | 肺動脈高血圧症及び肺障害の治療に使用するための1,3‐ジヒドロイミダゾール‐2‐チオン誘導体 | |
EA007952B1 (ru) | Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии | |
CN100566719C (zh) | 用于治疗尤其是在糖尿病患者中的肾的功能障碍、疾病或者病症的药物组合物 | |
JP2019513727A (ja) | レンバチニブ及びエベロリムスを用いた腎細胞癌の治療 | |
CN103037861A (zh) | 黄嘌呤氧化酶抑制剂与血管紧张素ii受体拮抗剂的组合及其用途 | |
RU2785893C2 (ru) | Лечение почечно-клеточной карциномы ленватинибом и эверолимусом | |
EP4337205A1 (en) | Dosing regimens | |
JP4522261B2 (ja) | ブドウ膜黒色腫の処置 | |
CN116650490A (zh) | 化合物mt-1207在降低尿酸方面的应用 | |
JP2003528050A (ja) | 愛玩動物におけるピリミジン系のエンドセリンアンタゴニストの使用 | |
KR100222627B1 (ko) | 앙기오텐신-ii 수용체 길항제 및 칼슘 채널 차단제의 신규한 조성물 | |
JPH0672876A (ja) | 末梢血管抵抗改善による血圧降下剤 | |
CN101001630A (zh) | 选择性去甲肾上腺素再吸收抑制剂与pdev抑制剂的组合 | |
JP2006036712A (ja) | 脳梗塞予防または治療薬としてのビトロネクチン拮抗物質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090401 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110728 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110728 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20110812 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110812 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120228 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120501 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120508 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130212 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130513 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130625 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20130823 |